Matthew D. Hellmann, MD, on SCLC: Results From CheckMate 032
2017 ASCO Annual MeetingMatthew D. Hellmann, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)
Related Videos
Salah-Eddin Al-Batran, MD, on GEJ Adenocarcinoma: Results From the FLOT4-AIO Trial
Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research Krankenhaus Nordwest, discusses phase III study findings on perioperative chemotherapy with docetaxel, oxali...
Solange Peters, MD, PhD, on SCLC: Expert Perspective on CheckMate 032
Solange Peters, MD, PhD, of the University of Lausanne, examines the study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomize...
David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045
David I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizuma...
Ethan M. Basch, MD, on Symptom Monitoring: Findings on Overall Survival Rates
Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatme...
Eric Jonasch, MD, on Von-Hippel Lindau Disease: Pazopanib Trial
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses the largest prospective VHL disease-specific therapeutic trial performed to date, and the data tha...
